ClinicalTrials.gg
Active, not recruitingNCT07208461Updated Feb 11, 2026

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

A Phase 2 interventional study of Low dose antigen of LYB005 without A01B adjuvant and Low dose antigen of LYB005 with A01B adjuvant in Respiratory Syncytial Virus Infection Prevention, sponsored by Guangzhou Patronus Biotech Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Guangzhou Patronus Biotech Co., Ltd. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Planned enrollment
5th of 25
700 · median 132
Started
2025
with 3 others
Phase 2
6 of 30
1 open now
Primary completion
2026-03
later than 4 of 12 live
Registered
24th of 30
by date
Lead sponsor
2 of 30
Guangzhou Patronus Biotech Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 5th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2025, is one of 6 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 24th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

This is a randomized, observer-blinded, placebo-controlled Phase Ⅱ clinical trial to evaluate the immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.

Read the detailed description

A randomized, observer-blinded, placebo-controlled trial will be conducted to observe the immunogenicity and safety of LYB005 in adults aged 60 years and older. A total of 700 participants aged 60 years and older will be enrolled. Six formulations of LYB005 will be provided, three dose levels of antigen with or without A01B adjuvant. All participants will randomly receive six investigational vaccines and the placebo in a 1:1:1:1:1:1:1 ratio.

03

Conditions studied

  • Respiratory Syncytial Virus Infection Prevention

Keywords

  • Respiratory Syncytial Virus
  • Respiratory Syncytial Virus Infection
  • Recombinant Respiratory Syncytial Virus (RSV) Vaccine
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Residents aged 60 years and older (at the time of screening), regardless of gender;
  2. Participants can provide valid identification, voluntarily agree to participate in the study, and sign the Form, and are able to attend all planned follow-up visits and comply with the protocol requirements;
  3. Axillary temperature \< 37.3°C on the day of enrollment;
  4. Female participants must be (postmenopausal status defined as amenorrhea for 12 months without other medical causes) and must not intend to become pregnant by any means. Male participants must practice strict and avoid plans for procreation or sperm donation from the screening period until 1 month after vaccination. Acceptable methods of contraception include oral contraceptives (excluding emergency contraception), injectable or implantable contraception, sustained-release local contraceptives, contraceptive patches, intrauterine devices, sterilization, abstinence, condoms, diaphragms, and cervical caps.

Exclusion criteria

Exclusion Criteria:

  1. Allergy to the vaccine or its , or a history of anaphylactic shock or other serious adverse reactions to other vaccines;
  2. Previous vaccination against Respiratory Syncytial Virus;
  3. A confirmed diagnosis or etiological evidence of respiratory syncytial virus infection and related diseases caused by the infection within 12 months before enrollment;
  4. Has taken antipyretics, analgesics or anti-allergy drugs within 24 hours before enrollment;
  5. Has received any vaccine within 14 days before vaccination, or have received a within 28 days;
  6. Has received blood or blood-related products, including immunoglobulin, within 3 months prior to enrollment; or plan to use them during the study period;
  7. Individual with the following diseases: ①Has acute diseases or are in the acute exacerbation period of chronic diseases within 3 days before vaccination; ②Diagnosed with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; ③History of congenital or acquired immunodeficiency or diseases; Chronic administration (≥14 consecutive days) of (dose ≥ 20 mg/day prednisone or equivalent dose) or other within the past 3 months, with the exception of inhaled or topical steroids, or short-term use (\<14 consecutive days) of oral corticosteroids; ④Neurological diseases or family history (seizures, epilepsy, encephalopathy, etc.); history of psychiatric disorders or family history; ⑤Asplenia or functional asplenia; ⑥Severe or uncontrolled or hospitalization-required cardiovascular diseases, diabetes, blood and lymphatic system diseases, immune system diseases, liver and kidney diseases, respiratory system diseases, metabolic and skeletal system diseases, or malignant tumors; ⑦ for intramuscular injection and blood drawing, such as coagulation disorders, thrombosis or hemorrhagic diseases, or situations requiring continuous use of anticoagulants; ⑧Severe hypertension that cannot be controlled by medication (measured on-site: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
  8. History of major surgery within 12 weeks prior to enrollment (as determined by the investigator), or not fully recovered from the surgery, or having plans for major surgery during the anticipated period of the subject's participation in the study;
  9. History of long-term alcohol abuse and/or drug abuse;
  10. Individual who is currently participating in other research or unregistered product (drugs, vaccines, or devices, etc.) clinical studies, or plan to participate in other clinical studies before the end of this clinical study;
  11. Other conditions that may impact the subject's safety or influence the assessment of vaccine response, as determined by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Low dose antigen of LYB005 without A01B adjuvant

    Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (low dose antigen without A01B adjuvant) at Day 0.

    Biological: Low dose antigen of LYB005 without A01B adjuvant

  • Experimental
    Low dose antigen of LYB005 with A01B adjuvant

    Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (low dose antigen with A01B adjuvant) at Day 0.

    Biological: Low dose antigen of LYB005 with A01B adjuvant

  • Experimental
    Middle dose antigen of LYB005 without A01B adjuvant

    Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (middle dose antigen without A01B adjuvant) at Day 0.

    Biological: Middle dose antigen of LYB005 without A01B adjuvant

  • Experimental
    Middle dose antigen of LYB005 with A01B adjuvant

    Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (middle dose antigen with A01B adjuvant) at Day 0.

    Biological: Middle dose antigen of LYB005 with A01B adjuvant

  • Experimental
    High dose antigen of LYB005 without A01B adjuvant

    Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (high dose antigen without A01B adjuvant) at Day 0.

    Biological: High dose antigen of LYB005 without A01B adjuvant

  • Experimental
    High dose antigen of LYB005 with A01B adjuvant

    Participant aged 60 years and older will be vaccinated with 1 dose of LYB005 (high dose antigen with A01B adjuvant) at Day 0.

    Biological: High dose antigen of LYB005 with A01B adjuvant

  • Placebo comparator
    Placebo

    Participants aged 60 years and older will be vaccinated with 1 dose of placebo at Day 0.

    Biological: Placebo

Interventions

  • BiologicalLow dose antigen of LYB005 without A01B adjuvant

    0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.

  • BiologicalLow dose antigen of LYB005 with A01B adjuvant

    0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.

  • BiologicalMiddle dose antigen of LYB005 without A01B adjuvant

    0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.

  • BiologicalMiddle dose antigen of LYB005 with A01B adjuvant

    0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.

  • BiologicalHigh dose antigen of LYB005 without A01B adjuvant

    0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.

  • BiologicalHigh dose antigen of LYB005 with A01B adjuvant

    0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.

  • BiologicalPlacebo

    0.5 mL 0.9% sodium chloride (normal saline) injection per dose

06

What researchers measure

Primary outcomes

  1. The geometric mean titer (GMT) of Neutralizing Antibodies Against RSV A and RSV B

    Measured by microneutralization assay.

    Time frame: 30 days after vaccination

  2. Geometric Mean Fold Rise (GMFR) for Neutralizing Antibodies Against RSV A and RSV B

    Change from prevaccination in geometric mean fold rise of Neutralizing antibody titer Against RSV A and RSV B

    Time frame: 30 days after vaccination

Secondary outcomes

  1. The GMT of Neutralizing Antibodies Against RSV A and RSV B

    Measured by microneutralization assay.

    Time frame: 14 days, 3 months, 6 months and 12 months after vaccination after vaccination

  2. GMFR for Neutralizing Antibodies Against RSV A and RSV B

    Change from prevaccination in geometric mean fold rise of Neutralizing antibody titer Against RSV A and RSV B

    Time frame: 14 days, 3 months, 6 months and 12 months after vaccination

  3. The geometric mean concentration (GMC) for Pre-fusion Protein Specific Binding Antibodies

    Measured by Enzyme-Linked Immunosorbent Assay (ELISA).

    Time frame: 30 days, 3 months, 6 months and 12 months after vaccination

  4. GMFR for Pre-fusion Protein Specific Binding Antibodies

    Change from prevaccination in geometric mean fold rise of Pre-fusion Protein Specific Binding Antibodies

    Time frame: 30 days, 3 months, 6 months and 12 months after vaccination

  5. Occurrence of immediate adverse events

    The incidence and severity of any adverse events (AEs) within 30 minutes after vaccination

    Time frame: Within 30 minutes after vaccination

  6. Incidence of solicited AE

    Occurrence and severity of solicited local injection site reactions for 7 days (Day 0-Day 7) following vaccination. (i.e., pain, redness, swelling). Occurrence and severity of solicited systemic reactions for 7 days (Day 0-Day 7) following vaccination. (i.e., myalgia, fatigue, headache, chills, fever).

    Time frame: Within 0-7 days after vaccination

  7. Incidence of unsolicited AEs

    The incidence and severity of any unsolicited AEs, including all AEs, except solicited AEs reported Day 0\~30 after the vaccination.

    Time frame: Within 0~30 days after vaccination

  8. Occurrence of serious adverse events (SAEs) and adverse events of special interests (AESIs)

    Incidence and severity of Serious adverse events and adverse events of special interest within 12 months after vaccination.

    Time frame: 12 months after vaccination

07

Study locations

1 site
  • Center for Disease Control and Prevention of Dangyang City
    Dangyang, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2026, 5 months after the start.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 5 months is below that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2025
First posted
Oct 6, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Mar 2026
CompletionEst.
Dec 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07208461
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Oct 21, 2025
Primary completion
Mar 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 11, 2026

Study contacts

Yeqing Tong
principal investigator · Hubei Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion